UA125393C2 - Модулятори соматостатину та їх застосування - Google Patents

Модулятори соматостатину та їх застосування Download PDF

Info

Publication number
UA125393C2
UA125393C2 UAA201901274A UAA201901274A UA125393C2 UA 125393 C2 UA125393 C2 UA 125393C2 UA A201901274 A UAA201901274 A UA A201901274A UA A201901274 A UAA201901274 A UA A201901274A UA 125393 C2 UA125393 C2 UA 125393C2
Authority
UA
Ukraine
Prior art keywords
quinolin
difluorophenyl
fluoro
aminopiperidin
methylphenyl
Prior art date
Application number
UAA201901274A
Other languages
English (en)
Ukrainian (uk)
Inventor
Цзян Жао
Сандон Хан
Сун Хіі Кім
Сун Хии Ким
Шимяо Ванг
Юнфей Жу
Original Assignee
Крінетікс Фармасьютікалс, Інк.
Кринетикс Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Крінетікс Фармасьютікалс, Інк., Кринетикс Фармасьютикалс, Инк. filed Critical Крінетікс Фармасьютікалс, Інк.
Publication of UA125393C2 publication Critical patent/UA125393C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
UAA201901274A 2016-07-14 2017-07-12 Модулятори соматостатину та їх застосування UA125393C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662362493P 2016-07-14 2016-07-14
US201662411338P 2016-10-21 2016-10-21
PCT/US2017/041694 WO2018013676A1 (en) 2016-07-14 2017-07-12 Somatostatin modulators and uses thereof

Publications (1)

Publication Number Publication Date
UA125393C2 true UA125393C2 (uk) 2022-03-02

Family

ID=60941935

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201901274A UA125393C2 (uk) 2016-07-14 2017-07-12 Модулятори соматостатину та їх застосування

Country Status (24)

Country Link
US (6) US9896432B2 (enExample)
EP (2) EP4163276A1 (enExample)
JP (2) JP6967577B2 (enExample)
KR (2) KR102324042B1 (enExample)
CN (2) CN109715612B (enExample)
AU (2) AU2017296392B2 (enExample)
CA (1) CA3030423A1 (enExample)
DK (1) DK3484865T3 (enExample)
ES (1) ES2931472T3 (enExample)
HR (1) HRP20221279T1 (enExample)
HU (1) HUE060182T2 (enExample)
IL (1) IL264178B2 (enExample)
LT (1) LT3484865T (enExample)
MX (1) MX390120B (enExample)
NZ (1) NZ750174A (enExample)
PL (1) PL3484865T3 (enExample)
PT (1) PT3484865T (enExample)
RS (1) RS63776B1 (enExample)
SG (1) SG11201900349VA (enExample)
SM (1) SMT202200465T1 (enExample)
TW (1) TWI789355B (enExample)
UA (1) UA125393C2 (enExample)
WO (1) WO2018013676A1 (enExample)
ZA (1) ZA201900317B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3484865T3 (pl) 2016-07-14 2023-01-09 Crinetics Pharmaceuticals, Inc. Modulatory somatostatyny i ich zastosowania
WO2018170284A1 (en) 2017-03-16 2018-09-20 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
CA3088658A1 (en) 2018-01-17 2019-07-25 Crinetics Pharmaceuticals, Inc. Process of making somatostatin modulators
WO2019157458A1 (en) * 2018-02-12 2019-08-15 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3807248A4 (en) * 2018-05-29 2021-10-27 Council of Scientific and Industrial Research BICYCLIC TOPOISOMERASE I INHIBITOR COMPOUNDS, THEIR PREPARATION AND USE
JP7431813B2 (ja) 2018-09-18 2024-02-15 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターとその使用
JP2022540922A (ja) * 2019-07-17 2022-09-20 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターの結晶形態
TWI841768B (zh) * 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
SMT202500315T1 (it) * 2020-09-09 2025-11-10 Crinetics Pharmaceuticals Inc Formulazioni di un modulatore della somatostatina
CN117043149A (zh) 2021-02-17 2023-11-10 克林提克斯医药股份有限公司 促生长素抑制素调节剂的结晶形式
CA3216457A1 (en) * 2021-05-25 2022-12-01 Ajay Madan Uses of a somatostatin modulator for the treatment of disease
EP4378971A4 (en) 2021-09-28 2024-11-20 Denka Company Limited CHLOROPRENE BLOCK COPOLYMER, LATEX, LATEX COMPOSITION AND RUBBER COMPOSITION
AU2023207068A1 (en) * 2022-01-11 2024-07-11 Crinetics Pharmaceuticals, Inc. Uses of a somatostatin modulator for the treatment of carcinoid syndrome
EP4547654A1 (en) 2022-06-10 2025-05-07 Assia Chemical Industries Ltd. Solid state forms of paltusotine and process for preparation thereof
PE20251882A1 (es) * 2022-10-28 2025-07-22 Basecamp Bio Inc Agonistas del receptor de la somatostatina 2 y usos de estos
US20240254106A1 (en) 2022-12-13 2024-08-01 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
KR20250162795A (ko) 2023-03-28 2025-11-19 크리네틱스 파마슈티칼스, 인크. 간 기능장애가 있는 환자에게 팔투소틴을 투여하기 위한 조성물 및 방법
WO2025111318A1 (en) * 2023-11-22 2025-05-30 Crinetics Pharmaceuticals, Inc. Somatostatin subtype receptor 3 (sstr3) agonists and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1035154A (en) 1910-05-16 1912-08-13 Ernest G Clark Machine for rectifying perforated music and masters.
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
EP1451156A4 (en) 2001-11-27 2005-05-25 Merck & Co Inc 4-AMINOCHINOLINVERBINDUNGEN
WO2003066055A1 (en) * 2002-02-04 2003-08-14 F. Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
US7767817B2 (en) 2003-09-05 2010-08-03 Binghe Wang Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
EP1773343A4 (en) * 2004-07-13 2009-05-13 Glaxo Group Ltd ANTIBACTERIAL AGENTS
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
CN101365439B (zh) 2005-12-05 2012-12-26 克塞诺波特公司 左旋多巴前体药物甲磺酸盐、其组合物及其用途
EP1991540A1 (en) 2006-02-21 2008-11-19 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
WO2007103554A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
AU2007309708A1 (en) * 2006-03-13 2008-05-02 Merck Sharp & Dohme Corp. Somatostatin agonists
MX2011002367A (es) 2008-09-02 2011-04-04 Novartis Ag Inhibidores de cinasa biciclicos.
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
BR112013002182B8 (pt) * 2010-07-30 2023-02-28 Oncotherapy Science Inc Compostos derivados de quinolina, composição farmacêutica, inibidor de melk, agente modulador de expressão de melk, agente antitumor, agente terapêutico e/ou preventivo para uma doença que envolve a superexpressão de melk contendo os mesmos e uso dos referidos compostos
AU2012258977A1 (en) 2011-05-23 2014-01-16 Imago Pharmaceuticals, Inc. Inhibitors of LRRK2 kinase activity
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
DE102011113749A1 (de) 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
WO2013050996A2 (en) 2011-10-05 2013-04-11 Mapi Pharma Ltd. Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids
EP2871179A4 (en) * 2012-07-03 2016-03-16 Ono Pharmaceutical Co CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
PE20151203A1 (es) * 2012-10-16 2015-08-31 Janssen Pharmaceutica Nv MODULADORES DE QUINOLINILO UNIDOS A FENILO DE ROR-GAMMA-t
TWI628175B (zh) 2013-09-30 2018-07-01 日商小野藥品工業股份有限公司 具有體抑素受體致效活性的化合物及其醫藥用途
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CA2943643A1 (en) 2014-03-24 2015-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
US9902703B2 (en) 2015-07-01 2018-02-27 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
HK1255034A1 (zh) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途
EP3889145B1 (en) 2015-12-17 2024-02-21 Merck Patent GmbH 8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders
US10597393B2 (en) 2016-07-07 2020-03-24 Plantex Ltd. Solid state forms of Palbociclib dimesylate
PL3484865T3 (pl) * 2016-07-14 2023-01-09 Crinetics Pharmaceuticals, Inc. Modulatory somatostatyny i ich zastosowania
CA3088658A1 (en) 2018-01-17 2019-07-25 Crinetics Pharmaceuticals, Inc. Process of making somatostatin modulators
JP7431813B2 (ja) 2018-09-18 2024-02-15 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターとその使用
JP2022540922A (ja) 2019-07-17 2022-09-20 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターの結晶形態
SMT202500315T1 (it) 2020-09-09 2025-11-10 Crinetics Pharmaceuticals Inc Formulazioni di un modulatore della somatostatina

Also Published As

Publication number Publication date
BR112019000692A8 (pt) 2022-03-03
CN115557929A (zh) 2023-01-03
MX390120B (es) 2025-03-20
JP6967577B2 (ja) 2021-11-17
US10875839B2 (en) 2020-12-29
US10597377B2 (en) 2020-03-24
EP3484865A4 (en) 2019-12-25
SMT202200465T1 (it) 2023-01-13
EP3484865B1 (en) 2022-09-14
CA3030423A1 (en) 2018-01-18
US20190382367A1 (en) 2019-12-19
AU2017296392A1 (en) 2019-02-28
KR102324042B1 (ko) 2021-11-09
KR20210134838A (ko) 2021-11-10
NZ750174A (en) 2023-04-28
US9896432B2 (en) 2018-02-20
WO2018013676A1 (en) 2018-01-18
TWI789355B (zh) 2023-01-11
CN109715612B (zh) 2022-09-16
CN109715612A (zh) 2019-05-03
US20210171492A1 (en) 2021-06-10
DK3484865T3 (da) 2022-10-31
IL264178B1 (en) 2024-01-01
IL264178B2 (en) 2024-05-01
JP2019520415A (ja) 2019-07-18
RS63776B1 (sr) 2022-12-30
SG11201900349VA (en) 2019-02-27
MX2019000588A (es) 2019-09-09
US11414397B2 (en) 2022-08-16
US20190002431A1 (en) 2019-01-03
PT3484865T (pt) 2022-11-03
HRP20221279T1 (hr) 2022-12-23
AU2020277122A1 (en) 2020-12-24
EP3484865A1 (en) 2019-05-22
ES2931472T3 (es) 2022-12-29
AU2017296392B2 (en) 2020-09-24
HUE060182T2 (hu) 2023-02-28
LT3484865T (lt) 2022-11-10
IL264178A (en) 2019-02-28
JP2022028675A (ja) 2022-02-16
PL3484865T3 (pl) 2023-01-09
EP4163276A1 (en) 2023-04-12
KR20190026914A (ko) 2019-03-13
BR112019000692A2 (pt) 2019-04-24
US20180016252A1 (en) 2018-01-18
ZA201900317B (en) 2022-10-26
US20220380337A1 (en) 2022-12-01
US20200190053A1 (en) 2020-06-18
US10351547B2 (en) 2019-07-16
TW201805276A (zh) 2018-02-16

Similar Documents

Publication Publication Date Title
UA125393C2 (uk) Модулятори соматостатину та їх застосування
AU2016202949A1 (en) Novel nicotinamide derivative or salt thereof
EP3041841B1 (en) Triazolopyridine compounds, compositions and methods of use thereof
EP3752498B1 (en) Somatostatin modulators and uses thereof
EA040023B1 (ru) Модуляторы соматостатина и их применения
BR112019000692B1 (pt) Compostos moduladores de somatostatina, composição farmacêutica e uso do referido composto
HK40008169A (en) Somatostatin modulators and uses thereof
HK40008169B (en) Somatostatin modulators and uses thereof